Related Experiment Videos
Ocular side-effects associated with imatinib mesylate (Gleevec).
Frederick W Fraunfelder1, Jonathan Solomon, Brian J Druker
1Casey Eye Institute, Portland OR 97201, USA. eyedrug@ohsu.edu
Summary
Imatinib mesylate (Gleevec) commonly causes ocular side effects like periorbital edema and epiphora in cancer patients. Management is typically conservative for these Gleevec side effects.
Area of Science:
- Ophthalmology
- Pharmacology
- Oncology
Background:
- Imatinib mesylate (Gleevec) is a tyrosine kinase inhibitor used in cancer therapy.
- Ocular side effects associated with imatinib mesylate are not fully characterized.
- Understanding these adverse reactions is crucial for patient management.
Purpose of the Study:
- To describe ocular side effects of imatinib mesylate.
- To detail the clinical characteristics of these adverse reactions.
- To classify the likelihood of various ocular side effects.
Main Methods:
- Retrospective case series of 104 patients on imatinib mesylate.
- Chart review at Oregon Health & Science University's Cancer Center.
- Review of spontaneous reports (FDA, WHO) and Medline literature search.
Main Results:
- 70% of patients developed periorbital edema; 18% developed epiphora.
- Periorbital edema occurred at an average of 68 days post-initiation.
- WHO classification: Certain - periorbital edema; Probable - epiphora.
Conclusions:
- Periorbital edema and epiphora are the most frequent ocular side effects of imatinib mesylate.
- Clinical characteristics of imatinib-induced periorbital edema are described.
- Ocular side effect management is generally conservative.